4D Molecular Therapeutics, Inc.
FDMT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650648
In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding 4D Molecular Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 146 | 1 | 126 | −19 |
| Shares | 46.8M | 123.5K | 43.1M | −3.63M (−7.8%) |
| Value | $260.6M | $687.7K | $139.8M | −$120.1M (−46.2%) |
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Nuveen, LLC | 150,314 | $485.5K | 0.00% |
| Man Group plc | 51,952 | $167.8K | 0.00% |
| Graham Capital Management, L.P. | 43,080 | $139.1K | 0.00% |
| Harbor Capital Advisors, Inc. | 30,595 | $99.0K | 0.00% |
| SEI Investments Co | 28,432 | $91.8K | 0.00% |
| Virtus Investment Advisers, Inc. | 23,864 | $77.1K | 0.02% |
| Prelude Capital Management, LLC | 22,500 | $72.7K | 0.01% |
| Renaissance Technologies LLC | 19,553 | $63.2K | 0.00% |
| Russell Investments Group, Ltd. | 19,532 | $63.1K | 0.00% |
| Brevan Howard Capital Management LP | 14,800 | $47.8K | 0.00% |
| AQR Capital Management LLC | 14,340 | $46.3K | 0.00% |
| Y-Intercept (Hong Kong) Ltd | 12,627 | $40.8K | 0.00% |
| Bridgeway Capital Management, LLC | 12,484 | $40.3K | 0.00% |
| Dynamic Technology Lab Private Ltd | 12,074 | $39.0K | 0.01% |
| Skopos Labs, Inc. | 4,217 | $13.6K | 0.00% |
| SRS Capital Advisors, Inc. | 628 | $2.03K | 0.00% |
| Steward Partners Investment Advisory, LLC | 500 | $1.61K | 0.00% |
| EverSource Wealth Advisors, LLC | 4 | $13 | 0.00% |
Sold out (37)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
Not filed for Q1 2025 yet (1)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Nuveen Asset Management, LLC | 123,468 | $687.7K |